Current Report Filing (8-k)
August 10 2017 - 1:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): August 10, 2017
CELGENE CORPORATION
(Exact name of registrant as specified
in its charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
86 Morris Avenue, Summit, New Jersey
|
07901
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (908) 673-9000
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01. Other Events.
On August 10, 2017, Celgene Corporation (the “Company”)
issued $500,000,000 aggregate principal amount of 2.250% Senior Notes due 2021 (the “Notes”). The Notes were offered
pursuant to a shelf registration statement on Form S-3 (File No. 333-214279), which became immediately effective upon its
filing with the Securities and Exchange Commission (the “SEC”) on October 27, 2016. A preliminary Prospectus Supplement
dated August 1, 2017 relating to the Notes was filed with the SEC on August 1, 2017, and a final Prospectus Supplement dated August
1, 2017 was filed with the SEC on August 1, 2017.
Item 9.01 Financial Statements and Exhibits
Exhibit No.
|
|
Description
|
|
|
|
5.1
|
|
Opinion
of Proskauer Rose LLP
|
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
CELGENE CORPORATION
|
|
|
|
|
|
Date: August 10, 2017
|
By:
|
/s/ Thomas M.
Perone
|
|
|
|
Thomas M. Perone
|
|
|
|
Vice President, Assistant General Counsel and
Assistant Secretary
|
|
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
5.1
|
|
Opinion
of Proskauer Rose LLP
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024